Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB), a clinical-stage company focused on treatments for inflammatory diseases and severe respiratory disorders, announced that CEO Rand Sutherland, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 a.m. ET.
A live webcast and replay will be available on the company’s investor relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – UPB
In the Jun 3 session, UPB gained 5.24%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Cash balance
- $294.6 million
- Cash, cash equivalents and short-term investments as of March 31, 2026
- Net loss
- $40.6 million
- Net loss for the quarter ended March 31, 2026
- Net loss per share
- $0.75
- Net loss per share for the quarter ended March 31, 2026
- Collaboration revenue
- $1.0 million
- Collaboration revenue from Maruho for the three months ended March 31, 2026
- ATM program size
- $150,000,000
- Maximum aggregate amount of common stock in at-the-market offering with Leerink Partners
- ATM commission
- 3.0%
- Maximum commission rate on gross proceeds under sales agreement with Leerink Partners
- Shares outstanding
- 54,419,986
- Common shares outstanding as of March 20, 2026 per Schedule 13G/A
- Year-end cash
- $341.5 million
- Cash, cash equivalents and short-term investments as of December 31, 2025
Historical Context
-
Reported improved asthma control and reduced steroid use in VIBRANT trial participants.
-
Detailed Q1 2026 results, higher expenses, and cash runway through 2027.
-
Announced upcoming VIBRANT Phase 2 data presentations at ATS 2026.
-
Outlined Phase 3 plan for verekitug and reported Q4 and 2025 results.
-
Planned additional VIBRANT analyses presentation at AAAAI 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET.
A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay will be available on the Company's website following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.